Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 37221-37230 Newer>

The Motley Fool July 13, 2009 Brian Orelli	Finally! It's a Win, Isn't It? Eli Lilly and marketing partner Daiichi Sankyo finally got a Food and Drug Administration approval of their blood thinner, Effient (prasugrel), on Friday afternoon.
The Motley Fool July 13, 2009 Dayana Yochim	4 Ways to Spread Your Risk In order to get some quality Zs, you need a solid asset-allocation plan -- meaning a portfolio with a bunch of investments that don't always move in the same direction.
The Motley Fool July 13, 2009 Rick Aristotle Munarriz	5 Losers That Will Be Winners Despite the market's healthy rally since mid-March, several popular stocks have shed half of their value, if not more. Let's take a look at five of those that could bounce back very strong.
The Motley Fool July 13, 2009	Today's 5-Star Movers A list of today's top-moving stocks from the Motley Fool five-star stock list.
The Motley Fool July 13, 2009 Rick Aristotle Munarriz	7 Reasons Not to Worry This Week Here are seven companies that are projected to grow their bottom lines this week.
The Motley Fool July 13, 2009 Dave Mock	3 Reasons to Buy Ford Today Despite the dismal sales and bankruptcies at Chrysler and GM, some investors see many reasons to consider buying shares of automaker Ford today.
The Motley Fool July 13, 2009 Rick Aristotle Munarriz	3 Stocks That Blew the Market Away These three stocks beat analyst's estimates: Pepsi Bottling Group... A. Schulman... Ruby Tuesday...
The Motley Fool July 11, 2009 Rick Aristotle Munarriz	A Fool Looks Back Google, Microsoft, and Netflix were in the news this week, as well as suitors for Data Domain.
The Motley Fool July 11, 2009 Rick Aristotle Munarriz	The Fool's Look Ahead Banks, bellwethers, and black ink will decorate the week that lies ahead. Look for reports on CSX, Goldman Sachs, Gannett, Google, and Bank of America, Citigroup, and GE.
The Motley Fool July 10, 2009 Brian Orelli	Is the News Good or Bad? Who Cares! Sell! A trial comparing Merck's and Schering-Plough's cholesterol drug Zetia to Abbott Labs' Niaspan was ended early, causing a sell-off of Merck stock.
<Older 37221-37230 Newer> Return to current articles.